Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468080 | 0.74 | — | — | |
| SCHEMBL4473527 | 0.69 | ERN1 (0.36) | ERN1CA12CA1CA2CA4 | |
| SCHEMBL2762009 | 0.68 | — | — | |
| SCHEMBL1274782 | 0.63 | CA1 (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2885322 | 0.61 | CA1 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL10634123 | 0.60 | ACHE (0.42) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL7071376 | 0.60 | PDE4B (0.39) | CA12CA1CA2CA4CA7 | |
| SCHEMBL6188780 | 0.60 | CA12 (0.41) | CA12CA1CA2CA4CA7 | |
| SCHEMBL6189538 | 0.60 | ALDH1A1 (0.39) | CA12CA1CA2CA4CA7 | |
| SCHEMBL7454339 | 0.60 | CA12 (0.38) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | ERN1 469/4885CA12 4776/4885CA1 4700/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | ERN1 1244/4885CA12 4750/4885CA1 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.